Global serum metabolomics profiling of colorectal cancer (Review)

Amir Hashim,Nurul   Azmir; Ab‑Rahim,Sharaniza; Suddin,Leny  Suzana; Ahmad Saman,Mohd  Shahril; Mazlan,Musalmah

doi:10.3892/mco.2019.1853

Global serum metabolomics profiling of colorectal cancer (Review)

Authors:
- Nurul Azmir Amir Hashim
- Sharaniza Ab‑Rahim
- Leny Suzana Suddin
- Mohd Shahril Ahmad Saman
- Musalmah Mazlan
View Affiliations

Affiliations: Faculty of Medicine, Universiti Teknologi MARA, Cawangan Selangor, Sungai Buloh, Selangor 47000, Malaysia
Published online on: May 8, 2019 https://doi.org/10.3892/mco.2019.1853
Pages: 3-14
Copyright: © Amir Hashim et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Accurate diagnosis of colorectal cancer (CRC) relies on the use of invasive tools such as colonoscopy and sigmoidoscopy. Non‑invasive tools are less sensitive in detecting the disease, particularly in the early stage. A number of researchers have used metabolomics analyses on serum/plasma samples of patients with CRC compared with normal healthy individuals in an effort to identify biomarkers for CRC. The aim of the present review is to compare reported serum metabolomics profiles of CRC and to identify common metabolites affected among these studies. A literature search was performed to include any experimental studies on global metabolomics profile of CRC using serum/plasma samples published up to March 2018. The Quality Assessment of Diagnostic Accuracy Studies (QUADAS) tool was used to assess the quality of the studies reviewed. In total, nine studies were included. The studies used various analytical platforms and were performed on different populations. A pathway enrichment analysis was performed using the data from all the studies under review. The most affected pathways identified were protein biosynthesis, urea cycle, ammonia recycling, alanine metabolism, glutathione metabolism and citric acid cycle. The metabolomics analysis revealed levels of metabolites of glycolysis, tricarboxylic acid cycle, anaerobic respiration, protein, lipid and glutathione metabolism were significantly different between cancer and control samples. Although the majority of differentiating metabolites identified were different in the different studies, there were several metabolites that were common. These metabolites include pyruvic acid, glucose, lactic acid, malic acid, fumaric acid, 3‑hydroxybutyric acid, tryptophan, phenylalanine, tyrosine, creatinine and ornithine. The consistent dysregulation of these metabolites among the different studies suggest the possibility of common diagnostic biomarkers for CRC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Zhu J, Djukovic D, Deng L, Gu H, Himmati F, Abu Zaid M, Chiorean EG and Raftery D: Targeted serum metabolite profiling and sequential metabolite ratio analysis for colorectal cancer progression monitoring. Anal Bioanal Chem. 407:7857–7863. 2015. View Article : Google Scholar : PubMed/NCBI
3	American Cancer Society: Cancer facts and figures 2013. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2013/cancer-facts-and-figures-2013.pdfAccessed Month day, year.
4	Wang D, Li W, Zou Q, Yin L, Du Y, Gu J and Suo J: Serum metabolomic profiling of human gastric cancer and its relationship with the prognosis. Oncotarget. 8:110000–110015. 2017.PubMed/NCBI
5	Chinnaiyan P, Kensicki E, Bloom G, Prabhu A, Sarcar B, Kahali S, Eschrich S, Qu X, Forsyth P and Gillies R: The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. Cancer Res. 72:5878–5888. 2012. View Article : Google Scholar : PubMed/NCBI
6	Hadi NI, Jamal Q, Iqbal A, Shaikh F, Somroo S and Musharraf SG: Serum metabolomic profiles for breast cancer diagnosis, grading and staging by gas chromatography-mass spectrometry. Sci Rep. 7:17152017. View Article : Google Scholar : PubMed/NCBI
7	Kumar N, Shahjaman M, Mollah MNH, Islam SMS and Hoque MA: Serum and plasma metabolomic biomarkers for lung cancer. Bioinformation. 13:202–208. 2017. View Article : Google Scholar : PubMed/NCBI
8	Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM and Kleijnen J: The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol. 3:252003. View Article : Google Scholar : PubMed/NCBI
9	Ma Y, Liu W, Peng J, Huang L, Zhang P, Zhao X, Cheng Y and Qin H: A pilot study of gas chromatograph/mass spectrometry-based serum metabolic profiling of colorectal cancer after operation. Mol Biol Rep. 37:1403–1411. 2010. View Article : Google Scholar : PubMed/NCBI
10	Bertini I, Cacciatore S, Jensen BV, Schou JV, Johansen JS, Kruhøffer M, Luchinat C, Nielsen DL and Turano P: Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res. 72:356–364. 2012. View Article : Google Scholar : PubMed/NCBI
11	Zhu J, Djukovic D, Deng L, Gu H, Himmati F, Chiorean EG and Raftery D: Colorectal cancer detection using targeted serum metabolic profiling. J Proteome Res. 13:4120–4130. 2014. View Article : Google Scholar : PubMed/NCBI
12	Guertin KA, Loftfield E, Boca SM, Sampson JN, Moore SC, Xiao Q, Huang WY, Xiong X, Freedman ND, Cross AJ and Sinha R: Serum biomarkers of habitual coffee consumption may provide insight into the mechanism underlying the association between coffee consumption and colorectal cancer. Am J Clin Nutr. 101:1000–1011. 2015. View Article : Google Scholar : PubMed/NCBI
13	Dowling P, Hughes DJ, Larkin AM, Meiller J, Henry M, Meleady P, Lynch V, Pardini B, Naccarati A, Levy M, et al: Elevated levels of 14-3-3 proteins, serotonin, gamma enolase and pyruvate kinase identified in clinical samples from patients diagnosed with colorectal cancer. Clin Chim Acta. 441:133–141. 2015. View Article : Google Scholar : PubMed/NCBI
14	Crotti S, Agnoletto E, Cancemi G, Di Marco V, Traldi P, Pucciarelli S, Nitti D and Agostini M: Altered plasma levels of decanoic acid in colorectal cancer as a new diagnostic biomarker. Anal Bioanal Chem. 408:6321–6328. 2016. View Article : Google Scholar : PubMed/NCBI
15	Farshidfar F, Weljie AM, Kopciuk K, Buie WD, Maclean A, Dixon E, Sutherland FR, Molckovsky A, Vogel HJ and Bathe OF: Serum metabolomic profile as a means to distinguish stage of colorectal cancer. Genome Med. 4:422012. View Article : Google Scholar : PubMed/NCBI
16	Farshidfar F, Weljie AM, Kopciuk KA, Hilsden R, McGregor SE, Buie WD, MacLean A, Vogel HJ and Bathe OF: A validated metabolomic signature for colorectal cancer: Exploration of the clinical value of metabolomics. Br J Cancer. 115:848–857. 2016. View Article : Google Scholar : PubMed/NCBI
17	Vahabi F, Sadeghi S, Arjmand M, Mirkhani F, Hosseini E, Mehrabanfar M, Hajhosseini R, Iravani A, Bayat P and Zamani Z: Staging of colorectal cancer using serum metabolomics with ¹HNMR Spectroscopy. Iran J Basic Med Sci. 20:835–840. 2017.PubMed/NCBI
18	Shu X, Xiang YB, Rothman N, Yu D, Li HL, Yang G, Cai H, Ma X, Lan Q, Gao YT, et al: Prospective study of blood metabolites associated with colorectal cancer risk. Int J Cancer. 143:527–534. 2018. View Article : Google Scholar : PubMed/NCBI
19	Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, Ni Y, Zhao A, Xu LX, Cai S and Jia W: Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res. 8:4844–4850. 2009. View Article : Google Scholar : PubMed/NCBI
20	Nishiumi S, Kobayashi T, Ikeda A, Yoshie T, Kibi M, Izumi Y, Okuno T, Hayashi N, Kawano S, Takenawa T, et al: A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS One. 7:e404592012. View Article : Google Scholar : PubMed/NCBI
21	Tan B, Qiu Y, Zou X, Chen T, Xie G, Cheng Y, Dong T, Zhao L, Feng B, Hu X, et al: Metabonomics identifies serum metabolite markers of colorectal cancer. J Proteome Res. 12:3000–3009. 2013. View Article : Google Scholar : PubMed/NCBI
22	Cross A, Moore SC, Boca S, Huang WY, Xiong X, Stolzenberg-Solomon R, Sinha R and Sampson JN: A prospective study of serum metabolites and colorectal cancer risk. Cancer. 120:3049–3057. 2014. View Article : Google Scholar : PubMed/NCBI
23	Zamani Z, Arjmand M, Vahabi F, Eshaq Hosseini SM, Fazeli SM, Iravani A, Bayat P, Oghalayee A, Mehrabanfar M, Haj Hosseini R, et al: A metabolic study on colon cancer using (1)h nuclear magnetic resonance spectroscopy. Biochem Res Int. 2014:3487122014. View Article : Google Scholar : PubMed/NCBI
24	Deng L, Gu H, Zhu J, Nagana Gowda GA, Djukovic D, Chiorean EG and Raftery D: Combining NMR and LC/MS using backward variable elimination: Metabolomics analysis of colorectal cancer, polyps, and healthy controls. Anal Chem. 88:7975–7983. 2016. View Article : Google Scholar : PubMed/NCBI
25	Uchiyama K, Yagi N, Mizushima K, Higashimura Y, Hirai Y, Okayama T, Yoshida N, Katada K, Kamada K, Handa O, et al: Serum metabolomics analysis for early detection of colorectal cancer. J Gastroenterol. 52:677–694. 2017. View Article : Google Scholar : PubMed/NCBI
26	Long Y, Sanchez-Espiridion B, Lin M, White L, Mishra L, Raju GS, Kopetz S, Eng C, Hildebrandt MAT, Chang DW, et al: Global and targeted serum metabolic profiling of colorectal cancer progression. Cancer. 123:4066–4074. 2017. View Article : Google Scholar : PubMed/NCBI
27	Nishiumi S, Kobayashi T, Kawana S, Unno Y, Sakai T, Okamoto K, Yamada Y, Sudo K, Yamaji T, Saito Y, et al: Investigations in the possibility of early detection of colorectal cancer by gas chromatography/triple-quadrupole mass spectrometry. Oncotarget. 8:17115–17126. 2017. View Article : Google Scholar : PubMed/NCBI
28	Kim SJ, Kim SH, Kim JH, Hwang S and Yoo HJ: Understanding metabolomics in biomedical research. Endocrinol Metab (Seoul). 31:7–16. 2016. View Article : Google Scholar : PubMed/NCBI
29	Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, Brown M, Knowles JD, Halsall A, Haselden JN, et al: Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc. 6:1060–1083. 2011. View Article : Google Scholar : PubMed/NCBI
30	Serkova NJ, Standiford TJ and Stringer KA: The emerging field of quantitative blood metabolomics for biomarker discovery in critical illnesses. Am J Respir Crit Care Med. 184:647–655. 2011. View Article : Google Scholar : PubMed/NCBI
31	Kastenmüller G, Raffler J, Gieger C and Suhre K: Genetics of human metabolism: An update. Hum Mol Genet. 24:R93–R101. 2015. View Article : Google Scholar : PubMed/NCBI
32	Ahn CS and Metallo CM: Mitochondria as biosynthetic factories for cancer proliferation. Cancer Metab. 3:12015. View Article : Google Scholar : PubMed/NCBI
33	Hay N: Reprogramming glucose metabolism in cancer: Can it be exploited for cancer therapy? Nat Rev Cancer. 16:635–649. 2016. View Article : Google Scholar : PubMed/NCBI
34	Jain RK, Munn LL and Fukumura D: Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer. 2:266–276. 2002. View Article : Google Scholar : PubMed/NCBI
35	Semenza GL: Hypoxia-inducible factors in physiology and medicine. Cell. 148:399–408. 2012. View Article : Google Scholar : PubMed/NCBI
36	Kaelin WG Jr and Ratcliffe PJ: Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol Cell. 30:393–402. 2008. View Article : Google Scholar : PubMed/NCBI
37	Ananieva E: Targeting amino acid metabolism in cancer growth and anti-tumor immune response. World J Biol Chem. 6:281–289. 2015. View Article : Google Scholar : PubMed/NCBI
38	Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R and Muller AJ: Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother. 63:721–735. 2014. View Article : Google Scholar : PubMed/NCBI
39	Peters JC: Tryptophan nutrition and metabolism: An overview. Adv Exp Med Biol. 294:345–358. 1991. View Article : Google Scholar : PubMed/NCBI
40	Grohmann U and Bronte V: Control of immune response by amino acid metabolism. Immunol Rev. 236:243–264. 2010. View Article : Google Scholar : PubMed/NCBI
41	Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ and Bradfield CA: An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 185:3190–3198. 2010. View Article : Google Scholar : PubMed/NCBI
42	Hitosugi T, Fan J, Chung TW, Lythgoe K, Wang X, Xie J, Ge Q, Gu TL, Polakiewicz RD, Roesel JL, et al: Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell. 44:864–877. 2011. View Article : Google Scholar : PubMed/NCBI
43	Pegg AE: Functions of polyamines in mammals. J Biol Chem. 291:14904–14912. 2016. View Article : Google Scholar : PubMed/NCBI
44	Hoshino Y, Terashima S, Teranishi Y, Terashima M, Kogure M, Saitoh T, Osuka F, Kashimura S, Saze Z and Gotoh M: Ornithine decarboxylase activity as a prognostic marker for colorectal cancer. Fukushima J Med Sci. 53:1–9. 2007. View Article : Google Scholar : PubMed/NCBI
45	Santos CR and Schulze A: Lipid metabolism in cancer. FEBS J. 279:2610–2623. 2012. View Article : Google Scholar : PubMed/NCBI
46	Menendez JA and Lupu R: Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 7:763–777. 2007. View Article : Google Scholar : PubMed/NCBI
47	Benlloch M, Ortega A, Ferrer P, Segarra R, Obrador E, Asensi M, Carretero J and Estrela JM: Acceleration of glutathione efflux and inhibition of gamma-glutamyltranspeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity. J Biol Chem. 280:6950–6959. 2005. View Article : Google Scholar : PubMed/NCBI